Results 201 to 210 of about 37,073 (238)

Research on Targeted Therapy for Malignant Tumors of the Biliary Tract. [PDF]

Onco Targets Ther
Yang Y, Zhong H, Zhang J, Wang P.
europepmc   +1 more source

Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors. [PDF]

Clin Cancer Res
Facchinetti F, Hollebecque A, Barbé R, Jang DM, Alonso-De-Castro B, Brayé F, Bigot L, Nobre C, Da Silva A, Méteau M, Delavigne M, Soares M, Italiano A, Rodriguez J, Mosele F, Beshiri K, Ducreux M, Boilève A, Nikolaev S, Alonso-Garcia I, Vasseur D, Smolenschi C, Bourien H, Cotteret S, Samaniego J, Bernard E, Nicotra C, Ngo-Camus M, Nakazawa S, Tselikas L, Badoual C, André F, Eck MJ, Olaussen KA, Loriot Y, Friboulet L.   +35 more
europepmc   +1 more source

Translational and Implementation Barrier in the Management of Biliary Tract Cancer: Diagnostic, Molecular, Therapeutic, and Patient-Centered Challenges. [PDF]

J Gastroenterol Hepatol
Bukhari RZ, Li Z, Li F, Hu H.
europepmc   +1 more source

Truncated FGFR2 Is a Clinically Actionable Oncogene in Multiple Cancers [PDF]

Nature, 2022
Somatic hotspot mutations and structural amplifications and fusions that affect fibroblast growth factor receptor 2 (encoded by FGFR2) occur in multiple types of cancer1.
Daniel Zingg, Siraj M Ali, Chang S Chan
exaly   +3 more sources

FGFR2 Alterations in Endometrial Carcinoma [PDF]

Modern Pathology, 2011
Fibroblast growth factor receptor 2 (FGFR2) is a tyrosine kinase receptor involved in many biological processes such as embryogenesis, adult tissue homeostasis and cell proliferation. Mutations in FGFR2 have been reported in up to 10-12% of endometrial carcinomas identical to those found in congenital craniofacial disorders.
Sonia Gatius, Xavier Matias-Guiu Guia, Xavier Dolcet   +2 more
exaly   +4 more sources